Moderator: Igor Nikolic

Dr. Igor Nikolic is a Research Fellow at European University Institute, Italy. He specialises and writes in the areas of standard essential patents, innovation and technical standardisation, intellectual property and competition law. He published a book ‘Licensing Standard Essential Patents: FRAND and the Internet of Things’ (Hart Publishing 2021) examining the law, policy, and economics of SEP licensing. At EUI he gives lectures on patent licensing and 5G policy issues. Igor has given presentations at various international conferences and published in academic journals on different topics related to standardisation, FRAND commitment, SEP disputes, the appropriate level chain for licensing and licensing negotiations groups.

He obtained PhD at University College London, where he is also associated as a Senior Fellow at UCL’s Centre for Law, Economics & Society. He taught competition and IP law at UCL, King’s College and the University of Turin and worked as an external consultant for the World Bank. Igor is also a qualified attorney at law advising on competition, intellectual property and regulatory issues.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More